Eidogen-Sertanty Licenses Target Informatics Platform to AstraZeneca
News Dec 16, 2005
Eidogen-Sertanty, Inc. has announced that AstraZeneca Pharmaceuticals LP has licensed access to its Target Informatics Platform™.
Under the agreement, scientists at AstraZeneca R&D Boston will access Eidogen-Sertanty’s Target Informatics Platform (TIP™) and EVE™ Comparative Visualization software to assist drug discovery efforts within their cancer and anti-infective therapeutic programs.
Through the integration of protein structural data and ligand binding site analysis, TIP is designed to bridge the knowledge gap between the disciplines of bioinformatics and cheminformatics.
"We are very excited that AstraZeneca R&D Boston has selected TIP to assist their drug discovery efforts," said Dr. Steve Muskal, CEO of Eidogen-Sertanty.
"We’re confident that TIP will help AstraZeneca scientists accelerate lead discovery programs across a wide variety of target families and therapeutic areas."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE